Pfizer Ends Study On Potential Lung Cancer Drug
Source: The Seattle Times
Friday 12th March, 2010
Pfizer Inc. said Thursday it discontinued a late-stage study of the drug candidate figitumumab in patients with late-stage lung cancer, citing a lack of effectiveness. ...
Read the full story at
The Seattle Times
Email this story to a friend
Have your say on this story
